– Quarter-end cash position of
– Phase 3 MANTRA trial completed enrollment five months ahead of previous guidance; topline data anticipated in first half of 2023 –
– Phase 2 MANTRA-2 trial ongoing as planned with interim data anticipated in fourth quarter 2022 –
– Management to host conference call and webcast today at
“Rain’s focus on clinical execution of the milademetan program was evidenced by the completion of enrollment of our Phase 3 MANTRA trial five months ahead of previous guidance. We believe the rapid enrollment in MANTRA reflects a patient population in LPS that may be larger than expected, and that exhibits a significant unmet medical need,” said
Key Developments, Presentations, Operational Updates and Upcoming Milestones
- Key Presentations
- Poster presented at 2022
American Association for Cancer Research (AACR) Annual Meeting titled, “Exploration of MDM2 gene amplification, co-mutation status, and prognosis in solid tumors” - Poster presented at 2022
American Society of Clinical Oncology (ASCO) Annual Meeting titled “Using CDKN2A loss in the context of wildtype TP53 to predict sensitivity for the MDM2 inhibitor milademetan”
- Poster presented at 2022
- Phase 3 Dedifferentiated Liposarcoma Trial (MANTRA)
- Enrollment now closed with 175 patients enrolled
- Topline data anticipated in the first half of 2023
- Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)
- Enrollment ongoing and interim data anticipated in the fourth quarter of 2022
- Phase 2 Trial for Milademetan in Merkel Cell Carcinoma (MANTRA-3)
- Trial commencement anticipated in the fourth quarter of 2022
- Phase 1/2 Basket Trial in Advanced Solid Tumors Exhibiting Loss of the CDKN2A Gene (MANTRA-4)
- Commencement of combination trial of milademetan with Roche’s FDA-approved IO therapy, atezolizumab, anticipated in the fourth quarter of 2022
Second Quarter Financial Results
For the three and six months ended
Research and development (R&D) expenses were
General and administrative (G&A) expenses were
Total non-cash stock-based compensation expense were approximately
As of
As of
Second Quarter 2022 Results Conference Call and Webcast Details
The management of
Replay of the call will be available by visiting the “Events” section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.
About Milademetan
Milademetan (also known as RAIN-32) is an oral small molecule inhibitor of the MDM2-p53 complex that reactivates p53. Milademetan has already demonstrated antitumor activity in an MDM2-amplified subtype of liposarcoma (LPS) and other solid tumors in a Phase 1 clinical trial, supported by a rationally-designed dosing schedule to mitigate safety concerns and widen the therapeutic window of MDM2 inhibition. Milademetan is being evaluated in an ongoing Phase 3 clinical trial in patients with LPS (MANTRA), as well as a Phase 2 tumor-agnostic basket trial in certain solid tumors (MANTRA-2). Rain anticipates commencing a Phase 2 clinical trial of milademetan (MANTRA-3), for the treatment of patients with wildtype p53 Merkel cell carcinoma who are also refractory to immune checkpoint inhibition (ICI), in the fourth quarter of 2022, as well as a Phase 1/2 clinical trial to evaluate the safety, tolerability and efficacy of milademetan in combination with Roche’s atezolizumab in patients with loss of cyclin-dependent kinase inhibitor 2A (CDKN2A) and wildtype p53 advanced solid tumors (MANTRA-4), in the fourth quarter of 2022. Milademetan has received Orphan Drug Designation from the
About
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, Rain’s ongoing and planned trials for milademetan, including patient enrollment, timing for topline and interim data, timing for the commencement of planned trials, expected trial designs, and expectations regarding the sufficiency of capital resources. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans,” “will”, “anticipates,” “goal,” “potential,” “expects” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Rain’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Rain’s business in general and limited operating history, Rain’s ability to execute on its strategy; Rain’s reliance on third parties to conduct and support its preclinical studies and clinical trials, positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical studies; the effect of the COVID-19 pandemic on Rain’s clinical trials and business operations, the impact of general economic, health, industrial or political conditions in
Investor Contact
646-597-6989
bob@lifesciadvisors.com
Media Contact
jtemperato@lifescicomms.com
Condensed Consolidated Statements of Operations | ||||||||||||||||||||
(in thousands, except share and per share amounts) | ||||||||||||||||||||
(unaudited) | ||||||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||||||
Operating expenses: | ||||||||||||||||||||
Research and development | $ | 14,257 | $ | 5,489 | $ | 27,812 | $ | 10,817 | ||||||||||||
General and administrative | 3,461 | 2,700 | 7,356 | 4,180 | ||||||||||||||||
Total operating expenses | 17,718 | 8,189 | 35,168 | 14,997 | ||||||||||||||||
Loss from operations | (17,718 | ) | (8,189 | ) | (35,168 | ) | (14,997 | ) | ||||||||||||
Other income: | ||||||||||||||||||||
Interest income | 107 | 6 | 163 | 14 | ||||||||||||||||
Net loss | $ | (17,611 | ) | $ | (8,183 | ) | $ | (35,005 | ) | $ | (14,983 | ) | ||||||||
Net loss per share, basic and diluted | $ | (0.66 | ) | $ | (0.39 | ) | $ | (1.32 | ) | $ | (1.23 | ) | ||||||||
Weighted-average shares used in computing net loss | ||||||||||||||||||||
per share, basic and diluted | 26,529,482 | 20,825,334 | 26,520,662 | 12,225,929 | ||||||||||||||||
SUMMARY BALANCE SHEET DATA | ||||||||||||||||||||
(in thousands) | ||||||||||||||||||||
2022 | 2021 (1) | |||||||||||||||||||
(unaudited) | ||||||||||||||||||||
Cash, cash equivalents and short-term investments | $ | 105,753 | $ | 140,218 | ||||||||||||||||
Total assets | 110,663 | 147,140 | ||||||||||||||||||
Stockholders' equity (deficit) | 98,285 | 130,504 | ||||||||||||||||||
(1) | Derived from audited financial statements | |||||||||||||||||||
Source:
2022 GlobeNewswire, Inc., source